# Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Source: https://onco.cc/trials/nct04644068/  
OnCo record `nct04644068` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Saruparib, Paclitaxel / nab-paclitaxel, Carboplatin in ovarian cancer and prostate cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT04644068 by AstraZeneca, with 702 participants enrolled, started 2020-11-12 and due to reach its primary completion in 2027-05-28. Interventions recorded: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd. Conditions listed: Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04644068
- Phase: 1/2
- Setting: A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
- Sponsor: AstraZeneca
- Enrolled: 702

## Sources

- ClinicalTrials.gov NCT04644068: https://clinicaltrials.gov/study/NCT04644068

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Camizestrant](https://onco.cc/drugs/camizestrant/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Saruparib](https://onco.cc/drugs/saruparib/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct04644068.json